2004/2005 Projected
Comparables* Median (Range)
Goal
New Invention Disclosures1
36
43 (9-86)
50
4
N/A
6
32
18 (4-79)
40
9 (1-33)
10
30
20
8
9 (0-24)
15
45
75
2
1 (0-4)
?
* Based on data from academic institutions with comparable levels of extramural research support ($125 million). Source: 2003 Licensing Survey published by the Association of University Technology Managers.
1 New Invention Disclosures are new discoveries that are reported to MCWRF using the MCW Invention Disclosure Form. Click to down load this form or see an example. 2 Inter-Institutional Agreements are put in place with other universities in the cases where the discovery is the result of research collaborations between MCW faculty and faculty at that institution. Click to down load this form or see an example. 3 Confidentiality Agreements are put in place with companies who are interested in more information on the discovery in order to assess the commercial potential. Click to down load this form or see an example. 4 Many companies elect to fund research in the discoverer's laboratory/clinic in order to further the value of the discovery. MCWRF works with MCW faculty to negotiate Sponsored Research Agreements. Click to down load this form or see an example. 5 Faculty Consulting Agreements with industry provide MCW faculty the opportunity to use their expertise and advise industry on new pharmaceuticals, medical devices, and research tools, including software. Click to down load this form or see an example. 6 License Agreements formally transfer to the company the commercial rights to develop, market, and sell commercial embodiments of the discovery – e.g. products. Click to see an example of a license agreement term sheet used in developing a license agreement. 7 Material Transfer Agreements provide an efficient mechanism to share new research tools (gene probes, monoclonal antibodies, proteins, etc.) developed at MCW and bring in tools developed at other institutions. Click to down load a template and see an example. 8 Some new discoveries are "platform" discoveries that could lead to a new diagnostic test and a therapy. The best way to develop these products is to keep them all together by forming a new company with faculty participating as chief scientific officers.